тел. +38 (044) 483-12-82

№2(7) 2024

Укр

DOI 10.37219/2528-8253-2024-2-73

Melnikov OF, Kotov OV, Kotov VO

RECURRENT TONSILLITIS IN THE SETTING OF KLEBSIELLA PNEUMONIAE-ASSOCIATED INFECTION

Melnikov Oleg F 
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of National Academy of Medical Science of Ukraine”; Kyiv, Ukraine.
Head of the Laboratory of Pathophysiology and Immunology (with a group of pathomorphology)
Doctor of Medical Sciences, Professor
Email: elenamelnykova@gmail.com
ORCID ID: https://orcid.org/0000-0002-1261-8647
https://www.scopus.com/authid/detail.uri?authorId=7006385903
https://www.scopus.com/authid/detail.uri?authorId=7003452154
 
Kotov Oleksandr V
Department of General Surgery, Surgery No. 3, Traumatology and Orthopaedics, Faculty of Postgraduate Education, Dnipro State Medical University
Candidate of Medical Sciences, Associate Professor
Email: a.vkotov@ukr.net
ORCID ID: https://orcid.org/0000-0002-1409-3020
 
Kotov Volodymyr O
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of National Academy of Medical Science of Ukraine”; Kyiv, Ukraine
Postgraduate student
Email: v.kotov.ent@gmail.com
ORCID ID: https://orcid.org/0009-0005-8979-8681

Abstracts

Among the gram-negative flora, Klebsiella pneumoniae is the leading causative agent of recurrent tonsillitis. The high level of pathogenicity and antibiotic resistance of Klebsiella pneumoniae infection is due to the following factors: high virulence, ability to form biofilms and the ability to produce a wide range of biologically active substances.  Having reviewed the studies of domestic and foreign authors, we concluded that the problem of studying the role of tonsils in the onset and maintenance of K. pneumoniae-associated infection has not been sufficiently covered and requires further research. Taking into account the general trend towards the development of immunosuppressive states in the population (the impact of SARS-CoV-2 infection, the associated use of high doses of glucocorticoids), the spread of antibiotic resistance among most infectious strains of microorganisms and as a consequence, an increase in the number of patients with sepsis and its complications, more attention should be paid not only to the manifested (clinically significant) focus of infection – pneumonia, pyelonephritis, cholangitis, etc., – but also to the identification of other latent foci of persistent K. pneumoniae infection and their sanitation (tonsils, intestines, genitourinary, bronchopulmonary and biliary systems).

Key words: recurrent tonsillitis, Klebsiella pneumoniae, biofilms, antibiotic resistance, bacteraemia.

Download .PDF

References

  1. Order of the Ministry of Health of Ukraine dated 06.04.2021 No. 639 “On Approval of the Unified Clinical Protocol for Primary, Secondary (Specialised) and Tertiary (Highly Specialised) Medical Care “Tonsillitis”. Link is available: https://moz.gov.ua/article/ministry-mandates/nakaz-moz-ukraini-vid-06042021–639-prozatverdzhennja-unifikovanogo-klinichnogo-protokolu-pervinnoi-vtorinnoispecializovanoi-ta-tretinnoi-visokospecializovanoi-medichnoi-dopomogitonzilit. [In Ukrainian].
  2. Bakar MA, McKimm J, Haque SZ, Majumder MAA, Haque M. Chronic tonsillitis and biofilms: a brief over-view of treatment modalities. J Inflamm Res. 2018 Sep 5:11:329-337. doi: 10.2147/JIR. S162486.
  3. Moshynets OV,  Baranovskyi TP, Cameron S,  Iungin OS, Pokholenko I, Jerdan R, et al. Azithromycin possesses biofilm–inhibitory activity and potentiates non-bactericidal colistin methanesulfonate (CMS) and polymyxin B against Klebsiella pneumonia. PLoS One. 2022 Jul 1;17(7):e0270983. doi: 10.1371/journal.pone.0270983.
  4. Oliva A, Mascellino MT, Cipolla A, D’Abramo A, De Rosa A, Savinelli S, et al. Therapeutic strategy for pan drug-resistant Klebsiella pneumoniae severe infections: short-course with colistin increases the in vivo and in vitro activity of double carbapenem regimen. Int J Infect Dis. 2015 Apr: 33:132-4. doi: 10.1016/j.ijid.2015.01.011.
  5. Klagisa R, Kroica J, Kise L. S. aureus and K. pneumoniae on the Surface and within Core of Tonsils in Adults with Recurrent Tonsillitis. Medicina. 2021 Sep 22;57(10):1002. doi: 10.3390/medicina57101002.
  6. Holt KE, Wertheim H, Zadoks RN, Baker S, Whitehouse CA, et al. Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in Klebsiella pneumoniae, an urgent threat to public health. Proc Natl Acad Sci USA. 2015 Jul 7;112(27):E3574-81. doi: 10.1073/pnas.1501049112. 
  7. Wang G, Zhao G, Chao X, Xie L, Wang H. The Characteristic of Virulence, Biofilm and Antibiotic Resistance of Klebsiella pneumoniae. Int J Environ Res Public Health. 2020 Aug 28;17(17):627. doi: 10.3390/ijerph17176278.
  8. Martin RM, Bachman MA. Colonization, Infection, and the Accessory Genome of Klebsiella pneumoniae. Front Cell Infect Microbiol. 2018 Jan 22:8:4. doi: 10.3389/fcimb.2018.00004.
  9. Cuberov M, Grau I, Tubau F, Pallares R, Dominguez MA, Linares J, Ardanuy C. Hypervirulent Klebsiella pneumoniae clones causing bacteraemia in adults in a teaching hospital in Barcelona, Spain (2007-2013). Clin Microbiol Infect. 2016 Feb;22(2):154-160. doi: 10.1016/j.cmi.2015.09.025.
  10. Russo TA, Marr CM. Hypervirulent Klebsiella pneumoniae. Clin Microbiol Rev. 2019 May 15;32(3):e00001-19. doi: 10.1128/cmr.00001-19.
  11. Piperaki ET, Syrogiannopoulos GA, Tzouvelekis LS, Daikos GL. Klebsiella pneumoniae: Virulence, Biofilm and Antimicrobial Resistance. Pediatr Infect Dis J. 2017 Oct;36(10):1002-1005. doi: 10.1097/INF.0000000000001675.
  12. Paczosa MK, Mecsas J. Klebsiella pneumoniae: Going on the Offense with a Strong Defense. Microbiol Mol Biol Rev. 2016 Jun 15;80(3):629-61. doi: 10.1128/MMMBR.00078-15.
  13. Hua KF, Yang FL, Chiu HW, Chou JC, Dong WC, Lin CN, et al. Capsular Polysaccharide Is Involved in NLRP3 Inflammasome Activation by Klebsiella pneumoniae Serotype K1. Infect Immun. 2015 Sep;83(9):3396-409. doi: 10.1128/IAI.00125-15.
  14. Shon AS, Bajwa RP, Russo TA. Hypervirulent (hypermucoviscous) Klebsiella pneumoniae: A new and dangerous breed. Virulence. 2013 Feb 15;4(2):107-18. doi: 10.4161/viru.22718.
  15. Llobet E, Martinez-Moliner V, Moranta D, Dahlstrom KM, Regueiro V, Tomas A, et al. Deciphering tissue-induced Klebsiella pneumoniae lipid A structure. Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):E6369-78. doi: 10.1073/pnas.1508820112.
  16. Lam M, Wyres KL, Judd LM, Wick RR, Jenney A, Brisse S, Holt KE. Tracking key virulence loci encoding aerobactin and salmochelin siderophore synthesis in Klebsiella pneumoniae. Genome Med. 2018 Oct 29;10(1):77. doi: 10.1186/s13073-018-0587-5.
  17. Peirano G, Ahmed-Bentley J, Fuller J, Rubin JE, Pitout JD. Travel-related carbapenemase-producing Gram-negative bacteria in Alberta, Canada: The first 3 years. J Clin Microbiol. 2014 May;52(5):1575-8. doi: 10.1128/JCM.00162-14.
  18. Doi Y, Wachino JI, Arakawa Y. Aminoglycoside Resistance: The Emergence of Acquired 16S Ribosomal RNA Methyltransferases. Infect Dis Clin North Am. 2016 Jun;30(2):523-537. doi: 10.1016/j.idc.2016.02.011.
  19. Guven Gokmen T, Nagiyev T, Meral M, Onlen C, Heydari F, Koksal F. NDM-1 and rmtC-Producing Klebsiella pneumoniae Isolates in Turkey. Jundishapur J Microbiol. 2016 Sep 18;9(10):e33990. doi: 10.5812/jjm.33990.
  20. Redgrave LS, Sutton SB, Webber MA, Piddock LJ. Fluoroquinolone resistance: Mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol. 2014 Aug;22(8):438-45. doi: 10.1016/j.tim.2014.04.007.
  21. Guillard T, de Jong A, Limelette A, Lebreil AL, Madoux J, de Champs C, et al. Characterization of quinolone resistance mechanisms in Enterobacteriaceae recovered from diseased companion animals in Europe. Vet Microbiol. 2016 Oct 15:194:23-29. doi: 10.1016/j.vetmic.2015.11.033.
  22. Nam YS, Cho SY, Yang HY, Park KS, Jang JH, Kim YT, et. al. Investigation of mutation distribution in DNA gyrase and topoisomerase IV genes in ciprofloxacin-non-susceptible Enterobacteriaceae isolated from blood cultures in a tertiary care university hospital in South Korea, 2005-2010. Int J Antimicrob Agents. 2013 Feb;41(2):126-9. doi: 10.1016/j.ijantimicag.2012.10.004.
  23. Martinez-Martinez L, Hernandez-Alles S, Alberti S, Tomas JM, Benedi VJ, Jacoby GA. In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum-cephalosporins. Antimicrob Agents Chemother. 1996 Feb;40(2):342-8. doi: 10.1128/AAC.40.2.342.
  24. Jacoby GA, Strahilevitz J, Hooper DC. Plasmid-mediated quinolone resistance. Microbiol Spectr. 2014 Oct;2(5):10.1128/microbiolspec.PLAS-0006-2013. doi: 10.1128/microbiolspec.PLAS-0006-2013.
  25. Mirzaii M, Jamshidi S, Zamanzadeh M, Marashifard M, Malek Hosseini SAA, Haeili M, et al. Determination of gyrA and parC mutations and prevalence of plasmid-mediated quinolone resistance genes in Escherichia coli and Klebsiella pneumoniae isolated from patients with urinary tract infection in Iran. J Glob Antimicrob Resist. 2018 Jun:13:197-200. doi: 10.1016/j.jgar.2018. 04.017.
  26. Schultsz C, Geerlings S. Plasmid-mediated resistance in Enterobacteriaceae: Changing landscape and implications for therapy. Drugs. 2012 Jan 1;72(1):1-16. doi: 10.2165/11597960-000000000-00000.
  27. Bush K. Bench-to-bedside review: The role of beta-lactamases in antibiotic-resistant Gram-negative infections. Crit Care. 2010;14(3):224. doi: 10.1186/cc8892.
  28. Canton R, Akova M, Carmeli Y, Giske CG, Glupczynski Y, Gniadkowski M, et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect. 2012 May;18(5):413-31. doi: 10.1111/j.1469-0691.2012.03821.x.
  29. Falagas ME, Kasiakou SK. Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005 May 1;40(9):1333-41. doi: 10.1086/429323.
  30. Antoniadou A, Kontopidou F, Poulakou G, Koratzanis E, Galani I, Papadomichelakis E, et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: First report of a multiclonal cluster. J Antimicrob Chemother. 2007 Apr;59(4):786-90. doi: 10.1093/jac/dkl562.
  31. Navon-Venezia S, Kondratyeva K, Carattoli A. Klebsiella pneumoniae: A major worldwide source and shuttle for antibiotic resistance. FEMS Microbiol Rev. 2017 May 1;41(3):252-275. doi: 10.1093/femsre/fux013.
  32. Srinivasan VB, Rajamohan G. KpnEF, a new member of the Klebsiella pneumoniae cell envelope stress response regulon, is an SMR-type efflux pump involved in broad-spectrum antimicrobial resistance. Antimicrob Agents Chemother. 2013;57(9):4449-6. doi: 10.1128/AAC.02284-12.
  33. De Majumdar S, Veleba M, Finn S, Fanning S, Schneiders T. Elucidating the regulon of multidrug resistance regulator RarA in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2013 Apr;57 (4):1603-9. doi: 10.1128/AAC.01998-12.
  34. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: A microbiological and molecular biological study. Lancet Infect Dis. 2016 Feb;16(2):161-8. doi: 10.1016/S1473-3099(15)00424-7.
  35. Macesic N, Nelson B, McConville TH, Giddins MJ, Green DA, Stump S, et.al. Emergence of Polymyxin Resistance in Clinical Klebsiella pneumoniae Through Diverse Genetic Adaptations: A Genomic, Retrospective Cohort Study. Clin Infect Dis. 2020 May 6;70(10):2084-2091. doi: 10.1093/cid/ciz623.
  36. van Ogtrop ML, Andes D, Stamstad TJ, Conklin B, Weiss W J, Craig W A, Vesga O. In vivo pharmacodynamic activities of two glycylcyclines (GAR936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother. 2000 Apr;44(4):943-9. doi: 10.1128/AAC.44.4.943-949.2000.
  37. Hall MJ, Williams SN, DeFrances CJ, Golosinskiy A. Inpatient care for septicemia or sepsis: a challenge for patients and hospitals. NCHS Data Brief. 2011 Jun:(62):1-8.
  38. Holland TL, Baddour LM, Bayer AS, Hoen B, Miro JM, Fowler VG. Infective endocarditis. Nat Rev Dis Primers. 2016 Sep 1:2:16059. doi: 10. 1038/nrdp.2016.59.
  39. Kavanagh N, Ryan EJ, Widaa A, Sexton G, Fennell J, O’Rourke S, et al. Staphylococcal osteomyelitis: disease progression, treatment challenges, and future directions. Clin Microbiol Rev. 2018 Feb 14;31(2):e00084-17. doi: 10.1128/CMR.00084-17.
  40. Torio CM, Moore BJ. Statistical Brief #204. National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2013. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK368492/.
  41. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016 Feb 23; 315(8):801-10. doi: 10.1001/jama.2016.0287.
  42. Reinhart K, Daniels R, Kissoon N, Machado FR, Schachter RD, Finfer S. Recognizing sepsis as a global health priority – a WHO resolution. N Engl J Med. 2017 Aug 3;377(5):414-417. doi: 10.1056/NEJMp1707170.
  43. Diekema DJ, Hsueh PR, Mendes RE, Pfaller MA, Rolston KV, Sader HS, et al. The microbiology of bloodstream infection: 20-year trends from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother. 2019 Jun 24; 63(7):e00355-19. doi: 10.1128/AAC.00355-19.
  44. Holmes C, Anderson MT, Mobley H, Bachman M. Pathogenesis of Gram-Negative Bacteremia. Clin Microbiol Rev. 2021 Mar 10;34(2):e00234-20. doi: 10.1128/CMR.00234-20.
  45. Gorrie CL, Mirceta M, Wick RR, Edwards DJ, Thomson NR, Strugnell RA, et al. Gastrointestinal carriage is a major reservoir of Klebsiella pneumoniae infection in intensive care patients. Clin Infect Dis. 2017 Jul 15;65(2):208-215. doi: 10.1093/cid/cix270.
  46. Davis GS, Waits K, Nordstrom L, Weaver B, Aziz M, Gauld L, et al. Intermingled Klebsiella pneumoniae populations between retail meats and human urinary tract infections. Clin Infect Dis. 2015 Sep 15;61(6):892-9. doi: 10.1093/cid/civ428.
  47. Xu M, Fu Y, Kong H, Chen X, Chen Y, Li L, et al. Bloodstream infections caused by Klebsiella pneumoniae: prevalence of blaKPC, virulence factors and their impacts on clinical outcome. BMC Infect Dis. 2018 Jul 31;18(1):358. doi: 10.1186/s12879-018-3263-x.
  48. Girometti N, Lewis RE, Giannella M, Ambretti S, Bartoletti M, Tedeschi S, et al. Klebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy. Medicine (Baltimore). 2014 Oct;93(17):298-309. doi: 10.1097/MD.0000000000000111.
  49. Wyres KL, Nguyen TNT, Lam MMC, Judd LM, van Vinh Chau N, Dance DAB, et al. Genomic surveillance for hypervirulence and multi-drug resistance in invasive Klebsiella pneumoniae from South and Southeast Asia. Genome Med. 2020 Jan 16;12(1):11. doi: 10.1186/s13073-019-0706-y.
  50. Tu YC, Lu MC, Chiang MK, Huang SP, Peng HL, Chang HY, et al. Genetic requirements for Klebsiella pneumoniae-induced liver abscess in an oral infection model. Infect Immun. 2009 Jul;77(7):2657-71. doi: 10.1128/IAI.01523-08.
  51. Klagisa R, Racenis K, Broks R, Balode AO, Kise L, Kroica J. Analysis of Microorganism Colonization, Biofilm Production, and Antibacterial Susceptibility in Recurrent Tonsillitis and Peritonsillar Abscess Patients. Int J Mol Sci. 2022 Sep 7;23 (18):10273. doi: 10.3390/ijms231810273.
  52. Kotov O, Desyaterik V, Mikhno S. [Microflora resistance in intra-abdominal infections and peritonitis].  Kharkiv School of Surgery. 2021;107(2): 90-96. doi: 10.37699/2308-7005.2.2021.17. [Article in Ukrainian].